Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain
Listen to this summary
The authors investigate the role of lanthionine synthetase C-like protein 1 (LanCL1) in chronic neuropathic pain, seeking to determine its potential as a therapeutic target. They demonstrate that the novel peptide ligand LAT8881 effectively reverses mechanical allodynia in rodent models of neuropathic pain by modulating LanCL1 activity, highlighting its critical role in neuropathic hypersensitivity. The study suggests that targeting LanCL1 could offer new avenues for treating neuropathic pain.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Pain
View all →More in Anesthesiology
View all →Sep 23, 2026 · The New England journal of medicine
Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
Sep 23, 2026 · The New England journal of medicine
Clinical Uses of Common Genetic Variants Associated with Common Diseases
Sep 23, 2026 · The New England journal of medicine
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Sep 23, 2026 · The New England journal of medicine
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Sep 22, 2026 · Lancet (London, England)
Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment
Sep 22, 2026 · Anesthesiology
Effect of In-line Clinical Decision Support to Improve Accuracy of American Society of Anesthesiologists Physical Status Documentation: A Two Center Evaluation of a Quality Intervention
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
